Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

FDA approves brepocitinib, the first oral, targeted therapy for adult dermatomyositis, backed by phase 3 VALOR data. For the ...

At a Chicago roundtable, clinicians detailed fragmented obesity and diabetes care, transplant-access barriers, and ...

Children and young adults who were unvaccinated and infected with COVID-19 were at an increased risk of developing ...

Body mass index (BMI) is recorded at nearly every clinical encounter, yet patients with obesity routinely reach specialty care only after years of untreated disease. Clinicians who treat them ...

Increasing travel burden was associated with lower surgery likelihood, with a 6% odds reduction per additional travel hour ...

Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally ...

Major depressive disorder (MDD) is a heterogeneous disorder with many unique symptom combinations. In this episode, ...

County-level CRC mortality fell substantially since 2000, but some counties still had rates more than 13 times the Healthy ...

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...